+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
All Ages
All Genders
ID07393659

Continued Access Study Providing Ongoing HIV Treatment for Participants from ViiV Healthcare Parent Studies

Led by ViiV Healthcare · Updated on 2026-08-14

181

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to provide continued access to HIV treatment for participants who completed previous ViiV Healthcare-sponsored or collaborative parent studies and are still benefiting from the study treatment but lack local access. The study focuses on collecting ongoing safety data while offering this extended treatment opportunity. Participants must have completed the treatment period in the parent study and continue to experience clinical benefits. Participants receive oral tablets of Fostemsavir and Dolutegravir DTG Lamivudine 3TC, with dosages depending on their weight. This open-label study includes a single group of participants transitioning from their parent studies to continued access. The study spans several years, allowing long-term treatment and monitoring. During the study, participants comply with scheduled visits, treatment plans, and study procedures. Researchers monitor safety by recording discontinuations, serious adverse events, and adverse events of special interest throughout the study period. Participation continues until withdrawal or study end, with ongoing assessment of treatment tolerability and safety.

CONDITIONS

Brief Title

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here